CDK7 and cancer: THZ1, a relatively selective covalent inhibitor of CDK7, effectively inhibits the growth of several cancer types such as T-cell acute lymphoblastic leukemia, MYCN-amplified neuroblastoma, and small cell lung cancer [17–19].